A Phase I/II Trial of Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
Latest Information Update: 08 Sep 2023
At a glance
- Drugs Cedazuridine/decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 18 Jan 2023 Planned End Date changed from 31 May 2025 to 30 Nov 2033.
- 18 Jan 2023 Planned primary completion date changed from 31 May 2025 to 30 Nov 2033.
- 16 May 2022 Planned End Date changed from 30 Apr 2025 to 31 May 2025.